NICE U-turn means it now recommends Bayer prostate cancer drug for routine NHS use

2 September 2016

The National Institute for Health and Care Excellence has today issued draft final guidance recommending German pharma major Bayer’s (BAYN: DE) Xofigo (radium-223 dichloride) as an option for treating prostate cancer, reversing an earlier decision not to back the drug.

When radium-223 was previously appraised by the NICE, the medicines cost-effectiveness watchdog for England and Wales, it was only recommended for people who had already received docetaxel treatment. It was not recommended for people for whom docetaxel was not suitable. This meant people who had not received docetaxel or for whom docetaxel was not suitable had to access radium-223 through the cancer drugs fund (CDF).

Following the decision to reform the CDF, NICE has been assessing the clinical and cost effectiveness of drugs currently in the old CDF.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK